Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Filings indexed 179 across all filing types
Latest filing 2026-05-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 93% confidence The document is a comprehensive financial report for Nanologica AB covering Q1 2026, including detailed financial statements, key performance metrics, segment analyses, cash flows, balance sheet items and narrative management commentary. It is clearly an interim/quarterly report (Delårsrapport Q1 2026) containing substantive financial data and analysis. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-20 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Interim Report Q1 2026” and provides a full set of quarterly financial statements, key figures, segment reporting, comparative periods, cash flow, balance sheet details, management commentary, and notes. It is not merely an announcement or a short earnings teaser but a comprehensive quarter-end report. This clearly matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-20 English
NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)
Regulatory Filings
2026-04-30 English
ANTAL AKTIER OCH RÖSTER I NANOLOGICA AB (PUBL)
Regulatory Filings
2026-04-30 Swedish
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-04-24 Swedish
Changes in the Management Team of Nanologica AB (publ)
Board/Management Information Classification · 90% confidence The document is a press release announcing changes in the company’s Group management team following an acquisition, specifying new CEO positions and an effective date. It is clearly an announcement of senior management changes and not a full report or other filing. Therefore, it falls under Board/Management Information (MANG).
2026-04-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.